Fluorine-18 FDG imaging in hepatocellular carcinoma using positron coincidence detection and single photon emission computed tomography

Liver

Volumn 22, Issue 1, 2002, Pages 51-56

  Verhoef, C ^a   Valkema, R ^a   De Man, R A ^a   Krenning, E P ^a   Yzermans, J N M ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

18 Deoxyglucose positron coincidence detection; Fluorine; Hepatocellular carcinoma; Imaging; Single photon emission computed tomography

Indexed keywords

ALPHA FETOPROTEIN; FLUORODEOXYGLUCOSE F 18; SUPERPARAMAGNETIC IRON OXIDE; TECHNETIUM 99M;

ADULT; AGED; ARTICLE; BENIGN TUMOR; CLINICAL ARTICLE; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; CONTRAST ENHANCEMENT; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC VALUE; ECHOGRAPHY; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; INTERMETHOD COMPARISON; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; MALE; METASTASIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PARTIAL HEPATECTOMY; POSITRON EMISSION TOMOGRAPHY; PREOPERATIVE EVALUATION; PROTEIN BLOOD LEVEL; SENSITIVITY ANALYSIS; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; TUMOR VOLUME;

ADULT; AGED; CARCINOMA, HEPATOCELLULAR; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; LIVER CIRRHOSIS; LIVER NEOPLASMS; MALE; MIDDLE AGED; PILOT PROJECTS; PROSPECTIVE STUDIES; RADIOPHARMACEUTICALS; SENSITIVITY AND SPECIFICITY; TOMOGRAPHY, EMISSION-COMPUTED; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON;

EID: 0036098916     PISSN: 01069543     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.0106-9543.2001.01593.x     Document Type: Article

References (46)

1. Advances in medical imaging for cancer diagnosis and treatment
2. The applications of PET in clinical oncology
3. Performance characteristics of a 511-keV collimator for imaging positron emitters with a standard gamma-camera
4. Instrumentation for coincidence imaging with multihead scintillation cameras
5. 18F-FDG detection with a dual-head coincidence camera: A review
6. Hepatocellular carcinoma. A worldwide problem and the major risk factors
7. Epidemiology of hepatocellular carcinoma
8. Hepatocellular carcinoma. Update on diagnosis and treatment
9. Review of hepatic imaging and a problem-oriented approach to liver masses
10. The changing role of radiology in imaging liver tumors: An overview
11. Recent developments in screening, diagnosis and surgical treatment of hepatocellular carcinoma
12. Hepatitis C and hepatocellular carcinoma
13. Screening for hepatocellular carcinoma
14. Imaging of hepatic cirrhosis
15. Primary hepatic malignant neoplasms
16. On the metabolism of tumors in the body
17. Elevated levels of glucose transport and transporter messenger RNA are induced by ras or src oncogenes
18. Physiochemical properties and isoenzyme composition of hexokinase from normal and malignant human tissues
19. Hexokinase, differentiation, and growth rates of transplanted tumors
20. Glucose-6-phosphatase activity in normal, precancerous, and neoplastic tissues
21. Comparative biochemistry of hepatomas. Carbohydrate enzymes in liver tumors of different growth rates
22. Metabolic trapping as a principle of radiopharmaceutical design: Some factors responsible for biodistribution of 18F 2-deoxy-2-fluoro-D-glucose
23. Enzyme patterns in fetal, adult, and neoplastic rat tissues
24. In vivo assessment of glucose metabolism in hepatocellular carcinoma with FDG-PET
25. Evaluation of liver tumors using fluorine-18-fluorodeoxyglucose PET. Characterization of tumor and assessment of effect of treatment
26. A case of hepatocellular carcinoma with lumbar bone metastasis with high uptake of 18F-fluorodeoxy galactose in PET
27. Fluorodeoxyglucose PET of abdominal and pelvic neoplasms: Potential role in oncologic imaging
28. Pattern of 2-deoxy-18F-fluoro-D-glucose accumulation in liver tumours: Primary, metastatic and after chemotherapy
29. Value of Fluorine-18-FDG-PET to monitor hepatocellular carcinoma after interventional therapy
30. Evaluation of benign vs malignant hepatic lesions with positron emission tomography
31. Positron emission tomography scanning in the evaluation of hepatocellular carcinoma
32. Fluorine-18 FDG positron emission tomography for imaging of hepatocellular carcinoma
33. Hepatocellular carcinoma outcomes based on indicated treatment strategy
34. Limited value of fluorine-18-fluorodeoxyglucose PET for the differential diagnosis of focal liver lesions in patients with chronic hepatitis C virus infection
35. Combined hepatocellular carcinoma and cholangiocarcinoma with high F-18 fluorodeoxyglucose positron emission tomographic uptake
36. Oncological applications of positron emission tomography with fluorine-18-fluorodeoxyglucose
37. Clinical usefulness of positron emission tomography with fluorine-18-fluorodeoxyglucose in the diagnosis of liver tumors
38. Detection of cervical lymph node metastases of nasopharyngeal carcinomas with technetium-99m tetrofosmin single photon emission computed tomography and comparison with computed tomography
39. Technetium-99m methoxy-isobutyl-isonitrile chest single photon emission computed tomography to detect mediastinal lymph node metastases in patients with non-small cell lung cancer: Comparison with computed tomography
40. Detection of esophageal carcinoma using single photon emission computed tomography with technetium-99m tetrofosmin
41. Role and limitations of magnetic resonance imaging in the diagnostic work-up of patients with liver cancer
42. Liver-specific MR imaging contrast agents
43. Imaging of diffuse liver disease
44. Small nodule detection in cirrhotic livers. Evaluation with US, spiral CT, and MRI and correlation with pathologic examination of explanted liver
45. Hepatocellular carcinoma treated with percutaneous radio-frequency ablation. Usefulness of power Doppler US with a microbubble contrast agent in evaluating therapeutic response: Preliminary results